<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Inebilizumab" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Inebilizumab</book-part-id>
      <title-group>
        <title>Inebilizumab</title>
        <subtitle>Short Chapter</subtitle>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Indomethacin" document-type="chapter">Indomethacin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="InfertilityAgents" document-type="chapter">Infertility Agents</related-object>
    </book-part-meta>
    <body>
      <p><italic toggle="yes">[Preliminary review chapter based on the FDA Product Labeling and Integrated Review</italic>
<italic toggle="yes">only.]</italic></p>
      <sec id="Inebilizumab.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Inebilizumab.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Inebilizumab is a monoclonal antibody to CD19 that is used to treat adults with neuromyelitis optica spectrum disorder accompanied by an autoantibody to aquaporin-4. Inebilizumab therapy is associated with an increased risk of infections and possibly reactivation of hepatitis B and tuberculosis, but it has not been associated with serum aminotransferase elevations during therapy or to instances of clinically apparent liver injury.</p>
        </sec>
        <sec id="Inebilizumab.Background">
          <title>Background</title>
          <p>Inebilizumab (in eb&#x0201d; i liz&#x02019; ue mab) is a humanized, cytolytic monoclonal antibody to CD19 that is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD), a severe neurologic disease marked by bilateral optic neuritis and transverse myelitis that is accompanied by a distinctive autoantibody to aquaporin-4 (antiAQP4). In many ways, NMOSD resembles multiple sclerosis (MS) and is similarly marked by spontaneous relapses and remissions. Yet NMOSD differs from MS by the absence of typical brain findings on magnetic resonance imaging and by the presence of antiAQP4, a possibly pathogenic antibody. Inebilizumab dramatically lowers peripheral B cells, and chronic therapy is effective in lowering immunoglobulin levels and reducing relapses of NMSOD. Inebilizumab was approved for treatment of adults with neuromyelitis optica spectrum disorder positive for anti-AQP4 in the United States in 2020. Inebilizumab is available in solution in single use vials of 100 mg/10mL under the brand name Uplizna. The recommended dose regimen is 300 mg by intravenous infusion at time 0 and 2 weeks later, followed by every 6 months. Patients should be screened for hepatitis B and tuberculous before starting therapy and should have serum immunoglobulin levels measured and be given any needed live viral vaccines beforehand. Premedication with acetaminophen, antihistamines, or corticosteroids is recommended. In prelicensure trials, common adverse events included infusion reactions, reduction in immunoglobulin levels, arthralgias, and urinary tract infections. Serious adverse events associated with inebilizumab therapy include severe infections, hypersensitivity reactions, and embryo-fetal toxicity. Because it lowers peripheral B cells, inebilizumab may cause reactivation of tuberculosis, hepatitis B, and herpes virus infections, and possibly lead to progressive multifocal leukoencephalitis.</p>
        </sec>
        <sec id="Inebilizumab.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In registration controlled trials, serum ALT elevations occurred in 21% of inebilizumab vs 23% of placebo recipients and were above 3 times the upper limit of normal (ULN) in 5 of 161 (3.1%) on inebilizumab vs only 1 of 51 (2%) on placebo. One patient receiving inebilizumab developed acute cholangitis with ALT and AST elevations above 5 times ULN but without jaundice and responding rapidly to antibiotics and biliary drainage. Since the approval of inebilizumab in 2020, there have been no case reports of clinically apparent liver injury attributed to its use. Monoclonal antibodies to CD19 have been used for other indications and similarly have been free of liver injury. These B cell directed monoclonal antibodies, however, are considered possible causes of reactivation of hepatitis B and prescreening for hepatitis B status is often recommended.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Inebilizumab.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The causes of the mild liver test abnormalities during inebilizumab therapy are not clearly known but appear to be related to the underlying condition or comorbidities such as nonalcoholic fatty liver disease or gallstone disease. Inebilizumab can cause hypersensitivity reactions including urticaria and rash, and liver injury might be a part of the immunoallergic reaction. Cases of reactivation of hepatitis B were not observed during prelicensure studies and should not occur with adequate prescreening and prophylaxis against reactivation.</p>
        </sec>
        <sec id="Inebilizumab.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The product label for inebilizumab does not recommend monitoring of routine liver tests during therapy but does recommend screening for hepatitis B before starting therapy and obtaining advice from a hepatologist regarding prophylaxis. Nevertheless, de novo elevations of serum aminotransferase levels above 5 times the ULN or baseline values should lead to temporary discontinuation and evaluation for other possible causes of liver injury, restarting therapy only when values return to normal or near normal and with careful subsequent monitoring.</p>
          <p>Drug Class: Neurological Disease Agents; <related-object link-type="booklink" source-id="livertox" document-id="MonoclonalAntibodies" document-type="book-part">Monoclonal Antibodies</related-object></p>
        </sec>
      </sec>
      <sec id="Inebilizumab.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Inebilizumab &#x02013; Uplizna&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Neurological Disease Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Inebilizumab">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Inebilizumab.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Inebilizumab.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Inebilizumab.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Inebilizumab.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Inebilizumab.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Inebilizumab.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Inebilizumab.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Inebilizumab</td>
                <td headers="hd_h_Inebilizumab.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/substance/381126899">1299440-37-1</ext-link>
</td>
                <td headers="hd_h_Inebilizumab.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Monoclonal Antibody</td>
                <td headers="hd_h_Inebilizumab.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">Not Available</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Inebilizumab.SELECTED_BIBLIOGRAPHY">
        <title>SELECTED BIBLIOGRAPHY</title>
        <p>References updated: 14 May 2024</p>
        <p>Abbreviations: AntiAQP4, antibody to aquaporin-4; NMOSD, neuromyelitis optica spectrum disorder; ULN, upper limit of the normal range.</p>
        <p><bold><italic toggle="yes">[Short Chapter</italic></bold>
<italic toggle="yes">information is based largely on FDA Product Labeling and the FDA Integrated Review accessible from the FDA website</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm"><italic toggle="yes">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</italic></ext-link><italic toggle="yes">. All other references have not been fully reviewed and annotated.]</italic></p>
        <ref-list id="Inebilizumab.SELECTED_BIBLIOGRAPHY.reflist0">
          <ref id="Inebilizumab.REF1">
            <mixed-citation publication-type="web">FDA. Integrated Review. 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761142Orig1s000MedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761142Orig1s000MedR.pdf</ext-link><annotation><p><italic toggle="yes">(FDA summary data on the safety and efficacy of inebilizumab, submitted in support of the application for approval as therapy of neuromyelitis optica spectrum disorder, mentions that ALT elevations arose in 21% of inebilizumab vs 23% of placebo recipients but were usually transient and mild, with one case of elevations above 5 times upper limit of normal [ULN] without jaundice that was shown to be due to acute cholangitis).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.chen.2016.107">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Monson</surname>
<given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Herbst</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>Y</given-names></string-name>. <article-title>Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies.</article-title>
<source>J Clin Med.</source>
<year>2016</year>;<volume>5</volume>:<fpage>107</fpage>.<pub-id pub-id-type="pmid">27886126</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.agius.2019.235">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Agius</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Klodowska-Duda</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Maciejowski</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Potemkowski</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Patra</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wesley</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.</article-title>
<source>Mult Scler.</source>
<year>2019</year>;<volume>25</volume>:<fpage>235</fpage>-<lpage>245</lpage>.<pub-id pub-id-type="pmid">29143550</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.frampton.2020.1259">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Frampton</surname>
<given-names>JE</given-names></string-name>. <article-title>Inebilizumab: first approval.</article-title>
<source>Drugs.</source>
<year>2020</year>;<volume>80</volume>:<fpage>1259</fpage>-<lpage>1264</lpage>.<pub-id pub-id-type="pmid">32729016</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.cree.2019.1352">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cree</surname>
<given-names>BAC</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname>
<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>
<given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Weinshenker</surname>
<given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Pittock</surname>
<given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Wingerchuk</surname>
<given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Fujihara</surname>
<given-names>K</given-names></string-name>, <etal>et al</etal>; <article-title>N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.</article-title>
<source>Lancet.</source>
<year>2019</year>;<volume>394</volume>(<issue>10206</issue>):<fpage>1352</fpage>-<lpage>1363</lpage>.<pub-id pub-id-type="pmid">31495497</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.rensel.2022.925">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rensel</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zabeti</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mealy</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Cimbora</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>She</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Drappa</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname>
<given-names>E</given-names></string-name>. <article-title>Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for &#x02a7e;4&#x02009;years in the N-MOmentum trial.</article-title>
<source>Mult Scler.</source>
<year>2022</year>;<volume>28</volume>:<fpage>925</fpage>-<lpage>932</lpage>.<pub-id pub-id-type="pmid">34595983</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.bennett.2022.104321">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bennett</surname>
<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Aktas</surname>
<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Rees</surname>
<given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Gunsior</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>She</surname>
<given-names>D</given-names></string-name>; <article-title>N-MOmentum study investigators. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.</article-title>
<source>EBioMedicine.</source>
<year>2022</year>;<volume>86</volume>:<elocation-id>104321</elocation-id>.<pub-id pub-id-type="pmid">36370634</pub-id>
</mixed-citation>
          </ref>
          <ref id="Inebilizumab.REF.cai.2024.1351782">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cai</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname>
<given-names>Z.</given-names></string-name>
<article-title>Case report: Identification of hepatitis B virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab.</article-title>
<source>Front Immunol.</source>
<year>2024</year>
<month>Feb</month>
<day>15</day>;<volume>15</volume>:<elocation-id>1351782</elocation-id>.<pub-id pub-id-type="pmid">38426084</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Inebilizumab.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Inebilizumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Inebilizumab: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Inebilizumab">Trials on Inebilizumab: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
